Candel Therapeutics (CADL) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Verastem (VSTM) over the past year, gaining 51.8% versus a loss of 9.3%. Over five years, CADL leads with a -1.7% price change compared with -75.5% for VSTM. Candel Therapeutics is the larger company by market cap ($760.6 million vs $758.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | VSTM |
|---|---|---|
| Share price | $9.94 | $8.38 |
| Market cap | $760.59M | $758.92M |
| 1-day change | +2.90% | +3.33% |
| YTD return | +75.93% | +5.05% |
| 1-year return | +51.76% | -9.28% |
| 5-year return | -1.73% | -75.51% |
| EPS (TTM) | $-1.46 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $10.82 |
| 52-week low | $4.35 | $3.43 |
| Distance from 52-week high | -29.00% | -22.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +118.81% | +79.00% |
| Average volume | 1.21M | 2.25M |
| Shares outstanding | 76.52M | 90.56M |
| Employees | 55 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed VSTM by 61.0 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
CADL vs VSTM FAQ
Which is bigger, Candel Therapeutics or Verastem?
Candel Therapeutics (CADL) is larger, with a market capitalization of $760.59M compared with $758.92M for Verastem (VSTM).
Which stock has performed better over the past year, CADL or VSTM?
CADL returned +51.76% over the past 12 months, compared with -9.28% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Verastem in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics and Biotechnology: Pharmaceutical Preparations for Verastem.